Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin versus best available therapy in relapsed or refractory myelofibrosis after JAK inhibitor treatment
MOH_2020-01-14_007392Phase 3Active, not recruiting
- Sponsor
- Kartos Therapeutics
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of navtemadlin in myelofibrosis (MF) (2 arms), sponsored by Kartos Therapeutics. Primary endpoints: Spleen response and Reduction in spleen volume at Week 24. Started Sep 2019; status: active, not recruiting.
02
Drugs
navtemadlin
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2020-01-14_007392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-14_007392.